Download medical necessity letter

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
Transcript
LETTER OF MEDICAL NECESSITY FOR HEREDITARY GYNECOLOGIC CANCER GENETIC
TESTING
Date:
Date of service/claim
To:
Utilization Review Department
Insurance Company Name, Address, City, State
Re:
Patient Name, DOB, ID #
ICD-9 Codes: (list codes)
This letter is to urge you to provide coverage for medically-indicated hereditary gynecologic cancer
genetic testing for the above named patient.
The personal and/or family history reported on the test requisition form raises significant concern
for an inherited predisposition to ovarian and/or uterine cancer and indicates a reasonable
probability of detecting a causative gene mutation. There are many genes known to predispose to
ovarian and/or uterine cancer and the ordered genetic test analyzes 9 high-risk, well characterized
genes associated with hereditary gynecologic cancer: BRCA1, BRCA2, EPCAM, MLH1, MSH2, MSH6,
PMS2, PTEN, and TP53. These genes substantially increase the risk for ovarian and/or uterine
cancer and other cancers.
This multi-gene test is the most efficient and cost-effective way to analyze the implicated
gynecologic cancer genes and has significant potential to identify a causative gene mutation in the
patient. Identification of a causative gene mutation will clarify the patient’s future cancer risk(s)
and target medical management.
The rationale for testing is that the presence of a mutation in one of these genes places this patient
at a substantially increased risk for developing cancer and thus would influence our management
recommendations significantly. An aggressive approach to reduce the risk of cancer is indicated in
individuals who carry a gene mutation that predisposes them to cancer. If a mutation is identified,
we would recommend high-risk management to reduce the patient’s risk of developing an advanced
stage cancer and subsequently dying of the disease. As such, I am ordering this genetic test as
medically necessary care and affirm that the patient has provided informed consent for genetic
testing.
Please contact me if I can provide you with additional information.
Sincerely,
Ordering Clinician Name (Signature Provided on Test Requisition Form)
Test Details
CPT codes:
Laboratory:
81211x1, 81213x1, 81292x1, 81294x1, 81295x1, 81297x1, 81298x1, 81300x1, 81403x1
Ambry Genetics Corporation (TIN 33-0892453 / NPI 1861568784), a CAP-accredited and
CLIA-certified laboratory located at 15 Argonaut, Aliso Viejo, CA 92656